2026-06-06T17:41:40Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/302962026-02-03T11:27:41Zcom_10630_2254col_10630_37953

Izquierdo, Guillermo García-Agua-Soler, Nuria García-Ruiz, Antonio J. Rus, Macarena 2024-02-09T12:22:31Z 2024-02-09T12:22:31Z 2015 G. Izquierdo, N. García-Agua Soler, M. Rus, A. J. García-Ruiz, Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies, Brain and Behavior, 2015; 5(6), e00337, doi: 10.1002/brb3.337 https://hdl.handle.net/10630/30296 10.1002/brb3.337 Objective: To assess the effectiveness of glatiramer acetate (GA) compared to other multiple sclerosis (MS) therapies in routine clinical practice. Materials and methods: Observational cohort study carried out in MS patients treated with GA (GA cohort) or other MS therapies –switched from GA– (non-GA cohort). Study data were obtained through review of our MS patient database. The primary endpoint was the Expanded Disability Status Scale (EDSS) scores reached at the end of treatment/last check-up. Results: A total of 180 patients were included: GA cohort n = 120, non-GA cohort n = 60. Patients in the GA cohort showed better EDSS scores at the end of treatment/last check-up (mean   SD, 2.8   1.8 vs. 3.9   2.2; P = 0.001) and were 1.65 times more likely to show better EDSS scores compared to the non-GA cohort (odds ratio, 0.606; 95%CI, 0.436–0.843; P = 0.003). Patients in the GA cohort showed longer mean time to reach EDSS scores of 6 (209.1 [95%CI, 187.6–230.6] vs. 164.3 [95%CI, 137.0–191.6] months; P = 0.004) and slower disability progression (hazard ratio, 0.415 [95%CI, 0.286–0.603]; P < 0.001). The annualized relapse rate was lower in the GA cohort (mean   SD, 0.5   0.5 vs. 0.8   0.5; P = 0.001) and patients’ quality of life was improved in this study cohort compared to the non-GA cohort (mean   SD, 0.7   0.1 vs. 0.6   0.2; P = 0.01). Conclusions: GA may slow down the progression of EDSS scores to a greater extent than other MS therapies, as well as achieving a greater reduction in relapses and a greater improvement in patients’ quality of life. Switching from GA to other MS therapies has not proved to entail a better response to treatment. eng http://creativecommons.org/licenses/by/4.0/ open access Attribution 4.0 Internacional Esclerosis múltiple - Tratamiento Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies journal article